Earnings summaries and quarterly performance for Vivos Therapeutics.
Executive leadership at Vivos Therapeutics.
Board of directors at Vivos Therapeutics.
Research analysts who have asked questions during Vivos Therapeutics earnings calls.
LW
Lucas Ward
Ascendiant Capital Markets
5 questions for VVOS
Also covers: LIQT
Robert Sassoon
Water Tower Research LLC
3 questions for VVOS
Also covers: VERU, YI, ZOM
SH
Scott Henry
Alliance Global Partners
2 questions for VVOS
Also covers: DERM, DYNT, EVGN +8 more
DK
Do Kim
Piper Sandler & Co.
1 question for VVOS
GK
Guyn Kim
Water Tower Research
1 question for VVOS
RS
Robert Sessions
Water Tower Research
1 question for VVOS
Recent press releases and 8-K filings for VVOS.
Vivos Therapeutics Closes Warrant Exercise, Raises $4.64 Million
VVOS
- Vivos Therapeutics, Inc. (VVOS) announced the closing of the exercise of certain outstanding warrants, resulting in approximately $4.64 million in gross proceeds.
- These warrants, originally issued in January 2023, November 2023, and February 20, 2024, were exercised at a reduced price of $2.34 per share.
- As consideration for the cash exercise, Vivos issued new unregistered warrants to purchase up to 3,964,712 shares of common stock at an exercise price of $2.09 per share.
- The company intends to use the net proceeds from this offering for working capital and general corporate purposes.
Jan 20, 2026, 10:31 PM
Vivos Therapeutics Announces Warrant Exercise for $4.64 Million Gross Proceeds
VVOS
- Vivos Therapeutics, Inc. announced a definitive agreement for the immediate exercise of certain outstanding warrants originally issued in January 2023, November 2023, and February 2024.
- The warrants, covering up to 1,982,356 shares, will be exercised at a reduced price of $2.34 per share.
- This transaction is expected to generate approximately $4.64 million in gross proceeds for the company.
- As consideration, Vivos will issue new unregistered warrants to purchase up to 3,964,712 shares of common stock at an exercise price of $2.09 per share.
- The company intends to use the net proceeds from this offering for working capital and general corporate purposes.
Jan 16, 2026, 1:00 PM
Vivos Reports Q3 2025 Revenue Surge Driven by Strategic Business Model Shift
VVOS
M&A
Revenue Acceleration/Inflection
New Projects/Investments
- VVOS completed the acquisition of Sleep Center of Nevada (SCN) in June 2025, initiating a strategic pivot to operating medical dental practices rather than solely relying on the dental community for distribution.
- In Q3 2025, the first full quarter of SCN's operations, VVOS reported a 76% year-on-year revenue surge to nearly $7 million, with 50% of this revenue attributed to the new Nevada services, including $2.2 million from diagnostic services and $1.3 million from treatment revenue.
- The new practice model demonstrates strong profitability, with EBITDA margins of 50-60% at the practice level, and high patient engagement, with 94% of referred patients progressing to a second visit and 64% accepting treatment.
- To scale efficiently, VVOS is pursuing an affiliation model, such as the recent Detroit partnership, which offers similar economics to acquisitions but with minimal upfront capital expenditure, aiming to accelerate the path to cash flow positive despite significant debt incurred for the SCN acquisition.
Dec 16, 2025, 4:00 PM
Vivos Discusses Strategic Pivot, SCN Acquisition Impact, and Financial Strategy
VVOS
M&A
Revenue Acceleration/Inflection
New Projects/Investments
- Vivos' 2025 strategic pivot is centered on the June acquisition of Sleep Center of Nevada (SCN), aiming to transform its business model.
- In Q3, Vivos reported a 76% year-on-year revenue surge to nearly $7 million, with 50% ($3.4 million) of this revenue coming from new Nevada services related to SCN. SCN's diagnostic services contributed $2.2 million, and Vivos' treatment services from SCN referrals added $1.3 million.
- The company is experiencing overwhelming patient demand at SCN, leading to facility and staff expansion. 94% of referred patients proceed to a second visit, and 64% of those accept treatment.
- Q3 G&A expenses increased by $3.4 million, with $1.8 million attributed to SCN's operating costs. Vivos anticipates a contribution margin above 50% from sleep clinics once fully scaled, despite current investment in growth.
- Vivos incurred significant debt for the SCN acquisition but expects the new model's profitability to enable debt servicing and eventual refinancing/retirement. New initiatives like the Detroit model and cardiology partnerships aim for high revenue potential with minimal capital outlay to accelerate cash flow positivity.
Dec 16, 2025, 4:00 PM
Vivos Therapeutics Pivots Business Model with Sleep Center Acquisition and Affiliation Strategy
VVOS
M&A
New Projects/Investments
Revenue Acceleration/Inflection
- Vivos Therapeutics initiated a strategic business model pivot in 2025, acquiring the Sleep Center of Nevada (SCN) in June 2025 to directly operate medical dental practices, shifting from its prior dental community distribution model.
- In Q3 2025, SCN generated $2.2 million in diagnostic service revenue, and Vivos recognized an additional $1.3 million in treatment revenue from SCN referrals, with new Nevada services contributing 50% of Vivos' total $6.8 million Q3 revenue.
- The company is experiencing overwhelming patient demand at SCN and has secured credentialing with major insurance payers for its doctors, which is expected to significantly boost Q4 2025 and future revenues after initial operational lags.
- Vivos has expanded its growth strategy with a capital-efficient affiliation model in Detroit, Michigan, avoiding upfront acquisition costs while retaining most economics, and is pursuing similar partnerships, including with large cardiology practices.
- Despite taking on significant debt, Vivos expects the high profitability (50-60% EBITDA margins at the practice level) and accretive revenue streams from its new model to enable debt servicing and eventual retirement or refinancing.
Dec 16, 2025, 4:00 PM
Vivos Therapeutics Announces Grand Opening of Affiliated Sleep Center Near Detroit, Michigan
VVOS
New Projects/Investments
Product Launch
Revenue Acceleration/Inflection
- Vivos Therapeutics, Inc. (NASDAQ: VVOS) announced the grand opening of its latest sleep testing and treatment center in Auburn Hills, Michigan, on December 16, 2025.
- This new center is an extension of Vivos' capital-efficient and scalable sleep center affiliation model, which leverages contractual alliances to expand the reach of its FDA-cleared diagnostic and therapeutic products and services for obstructive sleep apnea (OSA).
- The company expects this national expansion strategy, which includes future affiliations, to generate additional revenues and higher margin services revenue for Vivos.
Dec 16, 2025, 1:45 PM
Vivos Therapeutics, Inc. Secures Promissory Note
VVOS
Debt Issuance
- Vivos Therapeutics, Inc. entered into a Promissory Note with Avondale Capital, LLC for an original principal amount of $2,093,340 on December 5, 2025.
- The Note includes an original issue discount of $587,340 and transaction expenses of $6,000, resulting in net proceeds to the company of approximately $1,500,000.
- The company will make weekly payments of $69,778 starting December 12, 2025.
- The Note is unsecured but guaranteed by Vivos Therapeutics' wholly-owned subsidiary, Airway Integrated Management Company, LLC.
- A $286,140 discount is available if the note is repaid in full by January 4, 2026.
Dec 5, 2025, 10:12 PM
Vivos Reports Strong Q3 2025 Revenue Growth Driven by Strategic Pivot
VVOS
Earnings
Revenue Acceleration/Inflection
M&A
- Vivos reported a significant increase in revenue for Q3 2025, rising 76% to $6.8 million compared to Q3 2024, and 78% sequentially from Q2 2025, primarily driven by the acquisition of Sleep Center of Nevada (SCN) and the new sleep medical practice model.
- The company's net loss for Q3 2025 increased to $5.4 million, reflecting higher costs associated with the business model pivot and the integration of SCN. For the nine months ended September 30, 2025, general and administrative expenses increased by $5.7 million to $19.2 million.
- Vivos' strategic pivot to acquiring and affiliating with medical sleep practices, such as SCN, is showing initial success, with expectations for revenue growth to outpace expenses in coming quarters and a long-term goal of achieving cash flow break-even.
- As of September 30, 2025, Vivos reported cash and cash equivalents of $3.1 million, total liabilities of $23.1 million, and stockholders' equity of $2.5 million.
Nov 19, 2025, 10:00 PM
Vivos Reports Strong Q3 2025 Revenue Growth Driven by Strategic Acquisition
VVOS
Earnings
Revenue Acceleration/Inflection
M&A
- VVOS reported a 76% increase in Q3 2025 revenue to $6.8 million and a 20% increase for the nine months ended September 30, 2025, to $13.6 million, primarily driven by the acquisition of Sleep Center of Nevada (SCN) and new treatment center revenue.
- The company's net loss for Q3 2025 was $5.4 million, and $14.3 million for the first nine months of 2025, reflecting increased costs from SCN integration, general and administrative expenses, and the business model pivot.
- As of September 30, 2025, VVOS had $3.1 million in cash and cash equivalents, with total liabilities of $23.1 million and stockholders' equity of $2.5 million.
- Management views the Q3 results as a validation of its strategic pivot towards direct affiliations and acquisitions of medical sleep practices, anticipating this replicable model will drive future revenue growth, reduce cash burn, and lead to profitability.
Nov 19, 2025, 10:00 PM
VVOS Reports Strong Q3 2025 Revenue Growth Driven by Strategic Acquisition
VVOS
Earnings
M&A
Revenue Acceleration/Inflection
- VVOS reported a 76% increase in revenue to $6.8 million for the third quarter of 2025, compared to $3.9 million in Q3 2024, and a 78% sequential increase from Q2 2025.
- This growth was primarily driven by the acquisition of the Sleep Center of Nevada (SCN), which contributed an additional $2.7 million in service revenue and approximately $200,000 in product revenue during Q3 2025.
- For the three months ended September 30, 2025, the company's net loss increased to $5.4 million, reflecting higher costs associated with the business model pivot and integration of SCN.
- VVOS anticipates continued revenue growth in the coming quarters, expecting a three to six-month ramp to achieve optimal revenue levels as new dental providers and nurse practitioners are licensed and credentialed, with a goal of reaching cash flow break-even.
Nov 19, 2025, 10:00 PM
Quarterly earnings call transcripts for Vivos Therapeutics.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more